-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

Benzinga·08/26/2026 10:47:30
Listen to the news
Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.